BioSyent Inc.

Equities

RX

CA0906901081

Pharmaceuticals

Market Closed - Toronto S.E. 03:59:59 2024-04-26 pm EDT 5-day change 1st Jan Change
8.51 CAD 0.00% Intraday chart for BioSyent Inc. +0.12% -7.70%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BioSyent Inc.(TSXV:RX) dropped from S&P/TSX Venture Composite Index CI
BioSyent To Present At LD Micro New York Investor Conference MT
Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2022. CI
Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2023. CI
BioSyent Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BioSyent Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
BioSyent Inc. Seeks Acquisitions CI
Transcript : BioSyent Inc., Q4 2023 Earnings Call, Mar 13, 2024
BioSyent Declares First Quarter 2024 Dividend MT
BioSyent Inc. Declares First Quarter 2024 Dividend, Payable on March 15, 2024 CI
BioSyent Inc.(TSXV:RX) added to S&P/TSX Venture Composite Index CI
BioSyent Inc.'s Equity Buyback announced on December 13, 2022, has expired with 380,000 shares, representing 3.17% for CAD 2.89 million. CI
BioSyent Inc. (TSXV:RX) announces an Equity Buyback for 650,000 shares, representing 5.53% of its issued share capital. CI
BioSyent Inc. authorizes a Buyback Plan. CI
Biosyent Reports Q3 2023 Results MT
Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2022. CI
BioSyent Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : BioSyent Inc., Q3 2023 Pre Recorded Earnings Call, Nov 16, 2023
BioSyent Inc. Declares Fourth Quarter 2023 Dividend, Payable on December 15, 2023 CI
Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2022. CI
BioSyent Posts Higher Q2 Net Income, Revenue YOY MT
BioSyent Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
BioSyent Inc. Declares Third Quarter 2023 Dividend, Payable on September 15, 2023 CI
Transcript : BioSyent Inc., Q2 2023 Pre Recorded Earnings Call, Aug 22, 2023
BioSyent Launches Inofolic for Women with Polycystic Ovary Syndrome MT
Chart BioSyent Inc.
More charts
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
8.51 CAD
Average target price
9 CAD
Spread / Average Target
+5.76%
Consensus
  1. Stock Market
  2. Equities
  3. RX Stock
  4. News BioSyent Inc.
  5. BioSyent Declares First Quarter 2024 Dividend